Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) announced its earnings results on Friday. The company reported $0.22 EPS for the quarter, Zacks reports. Daiichi Sankyo updated its FY 2024 guidance to 0.840-0.840 EPS.
Daiichi Sankyo Trading Down 3.8 %
Shares of OTCMKTS DSNKY traded down $1.07 during trading on Tuesday, reaching $26.87. 196,807 shares of the stock were exchanged, compared to its average volume of 196,737. Daiichi Sankyo has a twelve month low of $25.11 and a twelve month high of $42.48. The business's 50-day moving average price is $28.43 and its 200 day moving average price is $32.88.
Daiichi Sankyo Company Profile
(
Get Free Report)
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.
Further Reading
Before you consider Daiichi Sankyo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daiichi Sankyo wasn't on the list.
While Daiichi Sankyo currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
